Detail for Micafungin
Basic Information
DrugID 69
DrugName Micafungin
DrugDetail Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.

http://www.drugbank.ca/drugs/DB01141

http://en.wikipedia.org/wiki/Micafungin

Indication For use in the treatment of candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy, alone or in combination with other antifungals, for the treatment of invasive aspergillosis.

http://www.drugbank.ca/drugs/DB01141

Structure Click to see the orginal picture.
Interaction
Drug Name PMIDLink Reference
Amphotericin B Yustes C, Guarro J. (2005) In vitro synergistic interaction between amphotericin B andagainst Scedosporium spp. Antimicrob Agents Chemother. 49(8):3498-500.
Amphotericin B Serena C, Pastor FJ, Gilgado F, Mayayo E, Guarro J. (2005) Efficacy ofin combination with other drugs in a murine model of disseminated trichosporonosis. Antimicrob Agents Chemother. 49(2):497-502.
Amphotericin B Serena C, Fern��ndez-Torres B, Pastor FJ, Trilles L, Laz��ra Mdos S, Nolard N, Guarro J. (2005) In vitro interactions ofwith other antifungal drugs against clinical isolates of four species of Cryptococcus. Antimicrob Agents Chemother. 49(7):2994-6.
Itraconazole Ru��z-Cendoya M, Rodriguez MM, Marin�� M, Pastor FJ, Guarro J. (2008) In vitro interactions of itraconazole andagainst clinically important filamentous fungi. Int J Antimicrob Agents. 32(5):418-20.
Itraconazole Marin�� M, Serena C, Pastor J, Quind��s G, Carrillo AJ, Guarro J. (2007) In vitro activity ofcombined with itraconazole against Candida spp. Int J Antimicrob Agents. 30(5):463-5.
Nikkomycin Z Brun YF, Dennis CG, Greco WR, Bernacki RJ, Pera PJ, Bushey JJ, Youn RC, White DB, Segal BH. (2007) Modeling the combination of amphotericin B, micafungin, and nikkomycin Z against Aspergillus fumigatus in vitro using a novel response surface paradigm. Antimicrob Agents Chemother. 51(5):1804-12.
Nikkomycin Z Chiou CC, Mavrogiorgos N, Tillem E, Hector R, Walsh TJ. (2001) Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob Agents Chemother. 45(12):3310-21.
Voriconazole Heyn K, Tredup A, Salvenmoser S, M��ller FM. (2005) Effect of voriconazole combined withagainst Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother. 49(12):5157-9.
Voriconazole Serena C, Fern��ndez-Torres B, Pastor FJ, Trilles L, Laz��ra Mdos S, Nolard N, Guarro J. (2005) In vitro interactions ofwith other antifungal drugs against clinical isolates of four species of Cryptococcus. Antimicrob Agents Chemother. 49(7):2994-6.
Amiodarone Nishi I., Sunada A., Toyokawa M., Asari S., Iwatani Y. (2009) In vitro antifungal combination effects ofwith fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species (vol 15, pg 1, 2009). Journal of Infection and Chemotherapy 15:123-124. DOI: 10.1007/s10156-009-0002-7
Flucytosine Nishi I., Sunada A., Toyokawa M., Asari S., Iwatani Y. (2009) In vitro antifungal combination effects ofwith fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species (vol 15, pg 1, 2009). Journal of Infection and Chemotherapy 15:123-124. DOI: 10.1007/s10156-009-0002-7
Amphotericin B Nishi I., Sunada A., Toyokawa M., Asari S., Iwatani Y. (2009) In vitro antifungal combination effects ofwith fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species (vol 15, pg 1, 2009). Journal of Infection and Chemotherapy 15:123-124. DOI: 10.1007/s10156-009-0002-7
Fluconazole Nishi I., Sunada A., Toyokawa M., Asari S., Iwatani Y. (2009) In vitro antifungal combination effects ofwith fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species (vol 15, pg 1, 2009). Journal of Infection and Chemotherapy 15:123-124. DOI: 10.1007/s10156-009-0002-7
Itraconazole Ruiz-Cendoya M., Rodriguez M.M., Marine M., Pastor F.J., Guarro J. (2008) In vitro interactions of itraconazole andagainst clinically important filamentous fungi. International Journal of Antimicrobial Agents 32:418-420. DOI: 10.1016/j.ijantimicag.2008.05.015.
Voriconazole Nishi I., Sunada A., Toyokawa M., Asari S., Iwatani Y. (2009) In vitro antifungal combination effects ofwith fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species (vol 15, pg 1, 2009). Journal of Infection and Chemotherapy 15:123-124. DOI: 10.1007/s10156-009-0002-7
Target
TargetName References EssentialGene? Link
1,3-beta-D-glucan-UDP glucosyltransferase No
1,3-beta-glucan synthase component FKS1 No
beta-1,3-glucan synthesis inhibitor No
PathWay
PathWay Name Path Picture
Starch and sucrose metabolism - Reference pathway (KO)